Kyverna Therapeutics (KYTX) Prepaid Assets (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Prepaid Assets came in at $5.3 million in Q1 2026, up 5.56% YoY from $5.0 million in Q1 2025, and up 42.7% on a QoQ basis from $3.7 million in Q4 2025.
Analysis
Kyverna Therapeutics (KYTX) Prepaid Assets (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Prepaid Assets data on file, last reported at $5.3 million in Q1 2026.
- Quarterly Prepaid Assets rose 5.56% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (up 5.56% YoY) and the FY2025 annual result came in at $3.7 million, down 19.95% from the prior year.
- Prepaid Assets improved to $5.3 million in Q1 2026, from $3.7 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $5.7 million in Q1 2024 to a low of $2.6 million in Q2 2024.
- A 4-year average of $4.0 million and a median of $3.8 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2024 — Prepaid Assets soared 48.09% — and 2025, when it dropped 19.95%.
- Tracing KYTX's Prepaid Assets over 4 years: stood at $3.1 million in 2023, then soared by 48.09% to $4.6 million in 2024, then retreated by 19.95% to $3.7 million in 2025, then jumped by 42.7% to $5.3 million in 2026.
- The last three Prepaid Assets figures came in at $5.3 million (Q1 2026), $3.7 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Kyverna Therapeutics | 505.44 Mn | 505.44 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.12 Mn |
| Mar 31, 2026 | 5.28 Mn |
| Dec 31, 2025 | 3.70 Mn |
| Sep 30, 2025 | 3.79 Mn |
| Jun 30, 2025 | 2.65 Mn |
| Mar 31, 2025 | 5.00 Mn |
| Dec 31, 2024 | 4.62 Mn |
| Sep 30, 2024 | 3.79 Mn |
| Jun 30, 2024 | 2.59 Mn |
| Mar 31, 2024 | 5.69 Mn |
| Dec 31, 2023 | 3.12 Mn |